Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
9.78
Dollar change
-0.26
Percentage change
-2.59
%
Index- P/E- EPS (ttm)-5.98 Insider Own8.20% Shs Outstand19.99M Perf Week-9.44%
Market Cap195.60M Forward P/E- EPS next Y-4.21 Insider Trans0.00% Shs Float18.36M Perf Month-6.86%
Income-90.86M PEG- EPS next Q-0.75 Inst Own47.56% Short Float3.57% Perf Quarter28.68%
Sales0.00M P/S- EPS this Y-1987.78% Inst Trans-14.61% Short Ratio1.85 Perf Half Y-11.01%
Book/sh9.44 P/B1.04 EPS next Y-10.19% ROA-76.72% Short Interest0.66M Perf Year-34.09%
Cash/sh5.71 P/C1.71 EPS next 5Y- ROE-80.93% 52W Range6.50 - 19.85 Perf YTD-37.23%
Dividend Est.- P/FCF- EPS past 5Y-69.33% ROI-48.13% 52W High-50.73% Beta-
Dividend TTM- Quick Ratio24.24 Sales past 5Y-20.00% Gross Margin- 52W Low50.46% ATR (14)0.79
Dividend Ex-Date- Current Ratio24.24 EPS Y/Y TTM14.43% Oper. Margin- RSI (14)43.10 Volatility5.02% 8.94%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price95.60
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-45.98% Payout- Rel Volume0.66 Prev Close10.04
Sales Surprise- EPS Surprise-7839.45% Sales Q/Q- EarningsNov 13 BMO Avg Volume354.21K Price9.78
SMA20-6.69% SMA50-6.05% SMA200-15.36% Trades Volume234,160 Change-2.59%
Date Action Analyst Rating Change Price Target Change
Nov-19-21Downgrade Maxim Group Buy → Hold
Dec-10-24 07:30AM
Dec-04-24 07:30AM
Nov-18-24 07:00AM
Nov-14-24 07:30AM
Nov-13-24 07:30AM
07:30AM Loading…
Oct-31-24 07:30AM
Oct-24-24 07:30AM
Oct-03-24 07:30AM
Oct-01-24 07:30AM
Sep-24-24 07:30AM
Sep-19-24 05:38PM
07:26AM
Sep-04-24 07:55AM
Aug-27-24 07:01PM
Aug-13-24 07:30AM
07:36AM Loading…
Aug-08-24 07:36AM
Aug-07-24 07:30AM
Jul-08-24 08:38AM
Jun-27-24 12:00PM
Jun-26-24 07:41AM
Jun-19-24 07:30AM
Jun-11-24 09:35AM
07:30AM
May-29-24 07:30AM
May-14-24 07:30AM
May-06-24 08:32AM
Apr-25-24 07:30AM
Apr-18-24 07:30AM
Apr-16-24 07:30AM
Apr-10-24 07:30AM
11:53AM Loading…
Mar-19-24 11:53AM
Mar-18-24 07:30AM
Mar-15-24 07:30AM
Mar-14-24 07:30AM
Mar-13-24 07:00AM
06:00AM
Mar-12-24 10:37PM
Feb-27-24 07:30AM
Feb-14-24 07:45AM
Feb-07-24 07:30AM
Jan-28-24 05:02PM
Jan-24-24 09:00AM
Jan-23-24 07:30AM
Jan-08-24 07:34AM
Jan-04-24 07:32AM
Dec-06-23 07:30AM
Dec-05-23 07:30AM
Nov-30-23 07:30AM
Nov-20-23 07:30AM
Nov-16-23 07:30AM
Nov-15-23 07:30AM
Nov-14-23 07:16PM
01:00PM
Nov-10-23 08:13AM
08:05AM
08:03AM
Nov-03-23 07:40AM
Nov-01-23 03:32PM
07:30AM
Oct-31-23 09:00AM
07:45AM
Oct-29-23 05:17PM
Oct-26-23 07:30AM
Oct-25-23 07:30AM
Oct-23-23 07:33AM
Oct-17-23 05:35PM
Oct-12-23 05:00PM
Oct-06-23 07:30AM
Oct-04-23 07:30AM
Oct-03-23 07:30AM
Sep-27-23 07:30AM
Sep-26-23 07:30AM
Sep-25-23 07:30AM
Sep-21-23 05:00PM
07:30AM
Sep-05-23 07:30AM
Aug-28-23 01:23PM
10:57AM
09:22AM
Aug-23-23 09:37PM
Aug-21-23 01:40PM
Aug-17-23 07:30AM
Aug-15-23 07:52AM
Aug-14-23 07:30AM
Aug-04-23 09:46AM
Aug-02-23 07:30AM
Aug-01-23 09:32AM
Jul-31-23 06:29PM
Jul-27-23 07:30AM
Jul-26-23 07:30AM
Jul-24-23 07:55AM
Jul-20-23 05:01PM
08:00AM
Jul-17-23 08:44AM
Jul-12-23 07:30AM
Jun-30-23 07:30AM
Jun-29-23 05:00PM
Jun-27-23 05:00PM
07:30AM
Jun-21-23 07:30AM
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.